Table I.
Participant Demographic and Clinical Characteristics
| Characteristic, % (n) | Overall, N=51 | Placebo + Counseling, N=26 | Extended-release Naltrexone + Counseling, N=25 | p value |
|---|---|---|---|---|
| Gender, male | 71% (36) | 73% (19) | 68% (17) | .69 |
| Race/ethnicity | .33 | |||
| White-non Hispanic | 16% (7) | 8% (2) | 24% (6) | |
| Black-non-Hispanic | 71% (36) | 73% (19) | 68% (17) | |
| Hispanic | 8% (4) | 12% (3) | 4% (1) | |
| Other | 6% (3) | 8% (2) | 4% (1) | |
| Age, mean (SD), years | 51.2 (8.2) | 51.2 (9.2) | 51.2 (7.6) | .99 |
| Education (n = 48) | .93 | |||
| Less than high school graduate | 23% (11) | 25% (6) | 21% (5) | |
| High school graduate or equivalent | 35% (17) | 33% (8) | 38% (9) | |
| At least some college | 42% (20) | 42% (10) | 42% (10) | |
| Employed full-time or part-time | 12% (6) | 16% (4) | 8% (2) | |
| Marital Status (n = 50) | .59 | |||
| Never married | 68% (34) | 68% (17) | 68% (17) | |
| Married/cohabitating | 12% (6) | 8% (2) | 16% (4) | |
| Separated/divorced/widowed | 20% (10) | 24% (6) | 16% (4) | |
| ART Adherence, HIV Biomarkers. VACS Index | ||||
| ART Adherence, mean (SD) | 55% (32) | 59% (31) | 51% (33) | .38 |
| Undetectable HIV viral loadᶧ | 51% (26) | 62% (16) | 40% (10) | .12 |
| CD4 count, cells/mm3, mean (SD)ᶧ | 522 (380) | 513 (423) | 457 (313) | ..62 |
| VACS Index score, mean (SD)ᶧ | 43 (26) | 44 (26) | 42 (26) | .28 |
| Substance Use Disorder and Treatment History | ||||
| Number of heavv drinkina davs in the past 30 days, mean (SD) | 14.7 (9.8) | 16.4 (8.4) | 11.3 (8.4) | .03 |
| Number of days with any drinking in the past 30 days, mean (SD) | 17.9 (8.8) | 19.2 (7.5) | 14.8 (8.7) | .06 |
| Alcohol abuse/dependence | 69% (35) | 65% (17) | 72% (18) | .26 |
| Drug abuse/dependence | 76% (39) | 73% (19) | 80% (20) | .56 |
| Addiction Severity Index alcohol composite | 0.26 (0.20) |
0.29 (0.22) | 0.23 (0.16) | .38 |
| Prior alcohol or drug treatment? | 65% (32) | 63% (15) | 68% (17) | .69 |
| Prior receipt for medications to help with drinking? | 12% (6) | 12% (3) | 12% (3) | .96 |
| Prior use of naltrexone | 4% (2) | 8% (2) | 0% (0) | |
| Prior use of acamprosate | 2% (1) | 0% (0) | 2% (1) | |
| Prior use of disulfiram | 6% (3) | 4% (1) | 8% (2) | |
Asterisk (*): Mann-Whitney U test.
ᶧ
indicates based on raw data.